Lumacaftor/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients

RATIONALE: Targeted cystic fibrosis (CF) therapy with lumacaftor/ivacaftor partly restores chloride channel function and improves epithelial fluid transport in the airways. Consequently, changes may occur in the microbiome, which is adapted to CF lungs. OBJECTIVES: To investigate the effects of luma...

Descripción completa

Detalles Bibliográficos
Autores principales: Neerincx, Anne H., Whiteson, Katrine, Phan, Joann L., Brinkman, Paul, Abdel-Aziz, Mahmoud I., Weersink, Els J.M., Altenburg, Josje, Majoor, Christof J., Maitland-van der Zee, Anke H., Bos, Lieuwe D.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053817/
https://www.ncbi.nlm.nih.gov/pubmed/33898610
http://dx.doi.org/10.1183/23120541.00731-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053817/
https://www.ncbi.nlm.nih.gov/pubmed/33898610
http://dx.doi.org/10.1183/23120541.00731-2020

Ejemplares similares